Drug-induced lupus (DIL) is an autoimmune phenomenon where a drug exposure leads to the development of systemic lupus erythematosus (SLE) like clinical features. DIL is a clear example of an environmental trigger leading to the development of lupus in a genetically susceptible individual. Hydralazine was the first agent to be associated with the development of lupus-like symptoms in 1954. Since then, more than 100 drugs have been identified as the cause of drug-induced lupus, with the list expanding with the development of newer biologic agents each year. DIL tends to be less severe than SLE, with symptoms usually resolving after discontinuation of the offending agent.
Hundreds of drugs have been reported to cause DIL. While some drugs have good evidence of association with DIL, there are case reports implicating several other drugs as a possible cause of DIL. Several herbal medications have also been reported to cause a lupus-like syndrome. Clinical and immunological features may vary for each agent responsible for the development of DIL.
Procainamide and hydralazine have the highest incidence of causing DIL, with risks reported as high as 30% with procainamide and 5% to 10% with hydralazine. All anti-TNF agents have been associated with DIL, with the risk being higher with etanercept and infliximab. Other drugs with definite association with DIL include interferon-alpha, minocycline, isoniazid, rifampin, phenytoin, penicillamine, quinidine, phenytoin, methyldopa, chlorpromazine, carbamazepine, ethosuximide, propylthiouracil, and sulfasalazine. Several other medications are thought to be possible causes for DIL with case reports being reported, including statins, ace-inhibitors, proton pump inhibitors, gold salts, non-steroidal anti-inflammatory agents (NSAIDs), oral contraceptives, etc. Herbal medications such as alfalfa sprouts, echinacea, and melatonin have also been liked to more lupus flares.
Drug-induced lupus represents 6% to 12% of all lupus cases, with an annual incidence of 15,000 to 30,000 new cases per year in the United States. The epidemiology of DIL is reflective of the population taking the particular drug responsible for DIL. Minocycline induced lupus is more common in younger females, while procainamide or hydralazine induced lupus is more common in the elderly population.
The pathophysiology of DIL is unclear and different mechanisms are responsible for the induction of autoimmunity by different lupus-inducing drugs. There are some genetic risk factors such as HLA-DR4, HLA-DR0301 and Complement C4 null allele which vary between different agents. Slow acetylators with genetic deficiency of N-acetyltransferase are at a higher risk of DIL, especially from procainamide and hydralazine.
Inhibition of DNA methylation is thought to contribute to the development of DIL from many agents including procainamide and hydralazine. The demethylation of CD4+ T cells makes them autoreactive by overexpression of the LFA-1 adhesion molecule. These autoreactive T-cells can then overstimulate autoantibody production by interaction with self class II MHC molecules on B-cells and induce apoptosis of macrophages by interacting with self class II MHC molecules on macrophages which release the highly antigenic apoptotic chromatin from the dying macrophages. This autoantibody production and release of the antigenic macrophage chromatin is thought to contribute to the development of lupus-like autoimmunity.
Skin rash is one of the most common clinical presentations of drug-induced lupus. The pathological examination of the biopsy from the skin rash in patients with DIL is similar to those with SLE. The subacute cutaneous lupus erythematosus (SCLE) rash is one of the common rashes which may reveal vacuolar interface dermatitis with lymphohistiocytic infiltration of the upper dermis in a perivascular pattern, epidermal atrophy, dead keratinocytes, and dermo-epidermal degeneration.
Drug-induced lupus may develop a few weeks to several months after starting the drug, which may make the diagnosis difficult. Further, it is not possible to differentiate DIL from SLE based on clinical features alone, although DIL tends to be milder and renal or CNS involvement, vasculitis, leukopenia, and pericarditis are rare.
Arthralgia is common and often is the first symptom and presents in up to 90% of the patients. Constitutional symptoms including myalgia, fever and weight loss are also common. Cutaneous involvement is frequent and may include photosensitivity, purpura, erythema nodosum, malar rash, and subacute cutaneous lupus erythematosus (SCLE) rash. Scarring alopecia, discoid lesions, and mucosal ulcers are less common in DIL than in SLE. Serositis especially pleuritis is also commonly seen. Although pericarditis has rarely been reported with DIL secondary to some drugs, large pericardial effusion or cardiac tamponade is rare to occur in DIL.
Hydralazine induced lupus is frequently manifested by arthralgia, myalgia, fever, rash (malar rash is common), hepatosplenomegaly, lymphadenopathy, and pleuritis. Rare cases of glomerulonephritis, neuropsychiatric manifestations and pericarditis have been reported. While arthralgia, myalgia, fever, and pleuritis are common in procainamide induced lupus, rash and lymphadenopathy are less common, and glomerulonephritis or CNS involvement is rare. Minocycline induced lupus is usually characterized by fever, arthralgia, arthritis, rash and rarely pneumonitis and cutaneous vasculitis.
Anti-TNF agents, which are the mainstay of treatment of rheumatoid arthritis now, have been frequently reported with positive autoantibodies as well as drug-induced lupus. While there is a high incidence of positive autoantibodies including ANA and Anti-dsDNA in patients treated with anti-TNF agents (up to 50%), only a few of those patients develop DIL (less than 1%). Skin rash, thrombocytopenia, leukopenia, hypocomplementemia and rarely hemolytic anemia are the manifestations of DIL secondary to anti-TNF agents. Notably, the development of DIL from one anti-TNF agent may not always lead to DIL from another anti-TNF agent. Symptoms of DIL resolve within a few weeks to months after discontinuation of the anti-TNF agent, however, the autoantibodies may remain positive for several years.
Both interferon-alpha and interferon-beta have been linked to the development of DIL. As the case with anti-TNF agents, autoantibody development including ANA and Anti-dsDNA is common, while DIL develops in less than 2% cases. Arthralgia, arthritis, and leukopenia are the usual manifestations.
Subacute cutaneous lupus erythematosus (SCLE) may be idiopathic but is drug-induced in about one-third of cases. Hydrochlorothiazide is the classic drug associated with SCLE. Other drugs reported to cause SCLE include terbinafine, anti-TNF agents, antiepileptics, proton pump inhibitors, NSAIDs, calcium channel blockers and Ace inhibitors. The rash appears in a photodistribution. Morphologically, SCLE presents as a papulosquamous psoriasiform to a lichenoid eruption, but it also can have a scaly annular morphology with central clearing. SCLE is associated with anti-Ro/SSA positivity greater than 3/4 of the time, speckled ANA, and 30% positivity with anti-La/SSB.
Laboratory evaluation is crucial but may not always be able to differentiate DIL from SLE. Cytopenias are less common, and if present, are mild. Methyldopa has been associated with hemolytic anemia while a positive coombs test has been reported with methyldopa, procainamide, and carbamazepine.
Autoantibody evaluation reveals a positive ANA, usually in a homogenous pattern, although the speckled pattern has been reported. Anti-histone antibodies are present in 75% of cases of DIL, although their utility in differentiating DIL from SLE is limited given their positivity in up to 75% of cases of SLE as well. Positive anti-histone antibodies are seen in DIL secondary to several drugs including hydralazine, procainamide, hydrochlorothiazide, chlorpromazine, isoniazid, quinidine, penicillamine, anti-TNF agents, although they are less frequently seen in DIL secondary to minocycline or propylthiouracil.
Anti-dsDNA antibodies are seen in more than 50% of cases of SLE and less than 5% cases of DIL, especially secondary to anti-TNF agents and interferon-alpha. Rare cases of positive Anti-dsDNA have been reported in DIL secondary to minocycline and isoniazid. Anti-Ro/SSA antibodies may be positive in SCLE, either idiopathic or secondary to hydrochlorothiazide.
Antiphospholipid antibodies including anticardiolipin antibodies and lupus anticoagulant have been reported in DIL secondary to chlorpromazine, procainamide, quinidine, and interferon-alpha. These are rarely associated with thrombotic events.
Antineutrophil cytoplasmic antibodies (ANCA) especially P-ANCA or atypical-ANCA have been reported in DIL secondary to minocycline, hydralazine, propylthiouracil, methimazole, and anti-TNF agents. Notably, up to 20% of patients with SLE can also have a positive ANCA.
Other autoantibodies against antigens including smith, ribonuclear protein (RNP), SCL70, centromere, Jo-1 are rare in DIL and may help differentiate DIL from other autoimmune disorders.
Laboratory evaluation shall also include evaluation of complements (C3 and C4), renal function including urine to evaluate for proteinuria, liver function. Skin biopsy for DIL is indistinguishable from SLE although it should be pursued in suspicious skin lesions to rule out other etiologies.
The mainstay of treatment is recognition and discontinuation of the offending drug. Development of positive ANA alone after receiving a drug shall not be a reason for discontinuation of the drug, although these patients shall be closely monitored for the development of DIL. Symptoms of DIL usually resolve within a few weeks of discontinuation of the medication, although rarely, they may last several months. NSAIDs or low dose corticosteroids may be considered for milder manifestations, with high dose corticosteroids reserved for more serious manifestations such as symptomatic pericardial effusion. As noted above, even though the symptoms of DIL resolve within few weeks of drug discontinuation, the autoantibodies can stay positive for several months to years, and their presence alone shall be a reason to use anti-inflammatory or immunosuppressive therapy.
In patients on anti-TNF agents presenting with fever, rash, and arthralgia, infections shall be ruled out first due to the immunocompromised state of these patients.
Drug-induced lupus carries a favorable prognosis with less morbidity and mortality as compared to SLE. In most cases, DIL resolves within a few weeks after discontinuation of the drug, with rare patients needing treatment for several months. Life-threatening disease is infrequent. However, early recognition is crucial in preventing prolonged hospitalizations or multiple outpatient visits due to uncertainty about the diagnosis.
Most patients do not experience severe complications of drug-induced lupus. Rare cases of glomerulonephritis may need corticosteroids with immunosuppressive agents, but the development of permanent renal damage is rare.
Many drugs can induce lupus and often these patients will present to the nurse practitioner, primary care provider, internist, and rheumatologist. However, it is important to get an elaborate drug history because the diagnosis may not be straight forward. In most cases, once the offending drug is discontinued, the symptoms gradually subside. However, if there is any organ dysfunction, then the patient needs to be monitored until the laboratory parameters are normal. The pharmacist should always keep a track of patient medications because it may be the first clue that a drug is involved in the patient's pathology. an interprofessional team approach to the evaluation and treatment of drug-induced lupus will provide the best outcome. [Level V]
|||REINHARDT DJ,WALDRON JM, Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy. Journal of the American Medical Association. 1954 Aug 21; [PubMed PMID: 13183772]|
|||Bojinca VC,Bojinca M,Gheorghe M,Birceanu A,Iosif CI,Balanescu SM,Balanescu AR, Stevens-Johnsons syndrome or drug-induced lupus - a clinical dilemma: A case report and review of the literature. Biomedical reports. 2018 Jul; [PubMed PMID: 29930803]|
|||He Y,Sawalha AH, Drug-induced lupus erythematosus: an update on drugs and mechanisms. Current opinion in rheumatology. 2018 Sep; [PubMed PMID: 29870500]|
|||Atzeni F,Turiel M,Capsoni F,Doria A,Meroni P,Sarzi-Puttini P, Autoimmunity and anti-TNF-alpha agents. Annals of the New York Academy of Sciences. 2005 Jun [PubMed PMID: 16126996]|
|||Shakoor N,Michalska M,Harris CA,Block JA, Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (London, England). 2002 Feb 16 [PubMed PMID: 11867114]|
|||De Rycke L,Kruithof E,Van Damme N,Hoffman IE,Van den Bossche N,Van den Bosch F,Veys EM,De Keyser F, Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis and rheumatism. 2003 Apr [PubMed PMID: 12687543]|
|||Chang C,Gershwin ME, Drug-induced lupus erythematosus: incidence, management and prevention. Drug safety. 2011 May 1; [PubMed PMID: 21513360]|
|||Katz U,Zandman-Goddard G, Drug-induced lupus: an update. Autoimmunity reviews. 2010 Nov [PubMed PMID: 20656071]|
|||Williams VL,Cohen PR, TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. International journal of dermatology. 2011 May [PubMed PMID: 21506984]|
|||Rönnblom LE,Alm GV,Oberg KE, Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Annals of internal medicine. 1991 Aug 1 [PubMed PMID: 2058872]|
|||Sosenko T,Pasula S,Brahmamdam R,Girnita D, When Chest Pain Reveals More: A Case of Hydrochlorothiazide-Induced Systemic Lupus Erythematosus. The American journal of case reports. 2019 Jan 7; [PubMed PMID: 30613100]|
|||Batra J,Kaur S,Kaushal S,Singh A, Lamotrigine-induced Systemic Lupus Erythematosus: A Diagnostic Dilemma. Indian dermatology online journal. 2018 Nov-Dec; [PubMed PMID: 30505789]|
|||Vaglio A,Grayson PC,Fenaroli P,Gianfreda D,Boccaletti V,Ghiggeri GM,Moroni G, Drug-induced lupus: Traditional and new concepts. Autoimmunity reviews. 2018 Sep; [PubMed PMID: 30005854]|
|||Kelly AS,De la Harpe Golden P,D'Arcy C,Lally A, Drug-induced lupus erythematosus secondary to pirfenidone. The British journal of dermatology. 2018 Jun; [PubMed PMID: 29266198]|
|||Sarkar R,Paul R,Pandey R,Roy D,Sau TJ,Mani A,Ruia AV,Mondal J, Drug-induced Lupus Presenting with Myocarditis. The Journal of the Association of Physicians of India. 2017 Jun; [PubMed PMID: 28782328]|
|||[PubMed PMID: 17153847]|
|||Zeitjian V,Mehdizadeh A, ANA-Negative Hydralazine-Induced Pericardial Effusion. Case reports in medicine. 2017; [PubMed PMID: 29391867]|
|||Laurinaviciene R,Sandholdt LH,Bygum A, Drug-induced cutaneous lupus erythematosus: 88 new cases. European journal of dermatology : EJD. 2017 Feb 1; [PubMed PMID: 27799135]|